FOSCARNET Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Foscarnet, and what generic alternatives are available?
Foscarnet is a drug marketed by Amneal, Avet Lifesciences, Fresenius Kabi Usa, Gland, Hospira, and Sciecure. and is included in six NDAs.
The generic ingredient in FOSCARNET is foscarnet sodium. There are seven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the foscarnet sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Foscarnet
A generic version of FOSCARNET was approved as foscarnet sodium by FRESENIUS KABI USA on January 29th, 2021.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FOSCARNET?
- What are the global sales for FOSCARNET?
- What is Average Wholesale Price for FOSCARNET?
Summary for FOSCARNET
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Drug Prices: | Drug price information for FOSCARNET |
| DailyMed Link: | FOSCARNET at DailyMed |
US Patents and Regulatory Information for FOSCARNET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal | FOSCARNET SODIUM | foscarnet sodium | SOLUTION;INTRAVENOUS | 216602-001 | Mar 1, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sciecure | FOSCARNET SODIUM | foscarnet sodium | SOLUTION;INTRAVENOUS | 213987-001 | Nov 29, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Gland | FOSCARNET SODIUM | foscarnet sodium | SOLUTION;INTRAVENOUS | 213001-001 | Apr 21, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Avet Lifesciences | FOSCARNET SODIUM | foscarnet sodium | SOLUTION;INTRAVENOUS | 213807-001 | Jun 5, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Fresenius Kabi Usa | FOSCARNET SODIUM | foscarnet sodium | SOLUTION;INTRAVENOUS | 212483-001 | Jan 29, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hospira | FOSCARNET SODIUM | foscarnet sodium | SOLUTION;INTRAVENOUS | 077174-002 | May 31, 2005 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
